A Single Dose, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Injections of LY3041658 in Healthy Participants
Latest Information Update: 21 Jun 2021
At a glance
- Drugs Eltrekibart (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 17 Jun 2021 Status changed from active, no longer recruiting to completed.
- 18 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2021 Status changed from suspended to recruiting.